{Reference Type}: Journal Article
{Title}: Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan.
{Author}: Chen LJ;Cheng CK;Yeung L;Yang CH;Chen SJ; ;
{Journal}: J Formos Med Assoc
{Volume}: 119
{Issue}: 2
{Year}: Feb 2020
{Factor}: 3.871
{DOI}: 10.1016/j.jfma.2019.04.012
{Abstract}: Polypoidal choroidal vasculopathy (PCV) is a prevalent retinal disease predominantly occurs in Asians that shares some similarities seen in neovascular age-related macular degeneration. Recent large multicenter clinical trials on intravitreal anti-vascular endothelial growth factor (VEGF) agents and photodynamic therapy (PDT) have shed lights on the management of PCV. The Taiwan National Health Insurance had granted limited anti-VEGF agents and PDT for patients with PCV after the approval of required data submission, especially fundus angiography, optical coherence tomography, and visual acuity. In order to best utilize these limited resources for the patients, an expert meeting was held to provide updated Taiwan consensus recommendations for the management of PCV, including initial therapy selection, assessment of treatment response, re-treatment/rescue treatment, and determination of treatment extension/follow-up schedule. An algorithm for treatment allocation under both initial and re-treatment setting was proposed. Further mechanistic and clinical studies are required to investigate the prognostic factors and optimal treatment protocols that will improve healthcare quality and reduce burden of disease and treatment for patients with PCV.